Request Trial
shuterstock-138839393
Lightspring / Shutterstock.com
27 November 2014Ranjna Mehta-Dutt and Neha Srivastava

Biologics in India: bridging the gap

Section 10(4)(ii)(D) of India’s Patents Act, 1970 mandates the disclosure of the source and geographical origin of biological material whenever it’s mentioned in a patent specification but not sufficiently described in it or made available to the public.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotech
Amgen hit with lawsuit over its proposed Opdivo biosimilar
16 September 2026   BMS is stepping up its defence of its blockbuster cancer drug Opdivo as Amgen moves closer to the biosimilar market.
Pharma
Beyond the primary patent: How pharma can build competitive barriers
16 September 2026   A medicine reaching the end of its primary patent term does not necessarily mean the market is open to generics. The complex patent landscape surrounding semaglutide shows how secondary patents covering indications, formulations and manufacturing processes can extend competitive barriers—and why careful freedom-to-operate analysis is critical before launch, says Ana Neves of Inventa.
Biotech
Australian biotech sues Grail over multi-cancer blood test
15 September 2026   Grail is facing a patent infringement lawsuit over its Galleri cancer detection test, as Clinical Genomics seeks to enforce its intellectual property while no longer being commercially operational.


Editor's picks

Perfect Pitch: Inside the scheme that gets junior lawyers selling to clients
Regulation & Industry
Perfect Pitch: Inside the scheme that gets junior lawyers selling to clients
14 September 2026

Editor's picks

Regulation & Industry
Perfect Pitch: Inside the scheme that gets junior lawyers selling to clients
14 September 2026
Regulation & Industry
The buyers' wishlist: What makes a life sciences deal stack up?
25 August 2026
MedTech
Abbott fends off Chinese rival’s patent challenge at UPC
18 August 2026
Regulation & Industry
Where Big Pharma is betting big in the M&A boom
29 July 2026
Regulation & Industry
Buying the brains: Why is Big Pharma shopping for innovation?
27 July 2026
Regulation & Industry
Why is 2026 already a record year for M&A activity?
17 July 2026

More features

Beyond the primary patent: How pharma can build competitive barriers
The ‘Triple Point’ professional: Why patent success requires science, law, and technology
The UPC plugs another gap in its procedural rulebook
Trump slaps 100% tariff on generic drugs in US manufacturing push
Pharmascience v Janssen: Canada court updates methods of medical treatment protection
‘Blatant imitation’: Indian court blocks copycat pharma branding
US life sciences damages averaged $33.5m between 2019-2025
Chadha & Chadha hires former Remfry & Sagar patent partner